Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effect of Tivantinib on the QTC Interval in Cancer Subjects

This study has been completed.
Sponsor:
Collaborator:
Medpace, Inc.
Information provided by (Responsible Party):
Daiichi Sankyo Inc.
ClinicalTrials.gov Identifier:
NCT01699061
First received: October 1, 2012
Last updated: September 30, 2013
Last verified: September 2013
  Purpose

The purpose of this study is to determine the effects of tivantinib on the QTc interval in patients with solid tumors


Condition Intervention Phase
Solid Tumors
Drug: Tivantinib
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: A PHASE 1 SINGLE-BLIND, SINGLE-SEQUENCE STUDY ASSESSING THE EFFECT OF TIVANTINIB ON THE QTC INTERVAL IN CANCER SUBJECTS

Resource links provided by NLM:


Further study details as provided by Daiichi Sankyo Inc.:

Primary Outcome Measures:
  • The time-matched difference in the QTcF interval at each timepoint after both single and multiple doses of tivantinib compared with placebo [ Time Frame: Baseline and 1, 2, 3, 4, 6, 8, and 12 hours post dose on Days 1, 2, and 5 (+3 days) ] [ Designated as safety issue: Yes ]
    Triplicate ECG measurements of the QTc interval will be taken at Screening (4 sets each 1 hour apart) and pre-dose and 1, 2, 3, 4, 6, 8, and 12 hours post dose on Days 1, 2, and 5 (+3 days)


Secondary Outcome Measures:
  • Estimated change in baseline adjusted QT, corrected QT interval (QTcB), individually corrected QT interval (QTcI) (if possible), heart rate, PR, QRS, & RR intervals at timepoints after both single and multiple doses of tivantinib compared with placebo [ Time Frame: Baseline and 1, 2, 3, 4, 6, 8, and 12 hours post dose on Days 1, 2, and 5 (+3 days) ] [ Designated as safety issue: Yes ]
    Triplicate ECG measurements of the QTc interval will be taken at Screening (4 sets each 1 hour apart) and pre-dose and 1, 2, 3, 4, 6, 8, and 12 hours post dose on Days 1, 2, and 5 (+3 days)

  • Plasma pharmacokinetic (PK) profiles of tivantinib and major metabolites of tivantinib after both single and multiple doses of tivantinib. [ Time Frame: Baseline and 1, 2, 3, 4, 6, 8, and 12 hours post dose on Days 1, 2, and 5 (+3 days) ] [ Designated as safety issue: Yes ]
    Blood samples for PK analysis will be obtained within 15 minutes following each pre-specified ECG measurement

  • Explore the tivantinib plasma concentration-QTc interval relationship [ Time Frame: Baseline and 1, 2, 3, 4, 6, 8, and 12 hours post dose on Days 1, 2, and 5 (+3 days) ] [ Designated as safety issue: Yes ]
    Triplicate ECG measurements of the QTc interval will be taken at Screening (4 sets each 1 hour apart) and pre-dose and 1, 2, 3, 4, 6, 8, and 12 hours post dose on Days 1, 2, and 5 (+3 days). Blood samples for PK analysis will be obtained within 15 minutes following each pre-specified ECG measurement. The relationship between plasma concentrations of tivantinib and the change from baseline in QTc will be quantified using a linear random coefficient regression model approach.


Enrollment: 38
Study Start Date: July 2012
Study Completion Date: May 2013
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Placebo tablet administered with a meal twice a day on Day 1
Drug: Placebo
Placebo tablet administered with a meal twice a day on Day 1
Experimental: Tivantinib
3 tivantinib tablets 120 mg administered twice daily with a meal starting on Day 2
Drug: Tivantinib
3 tivantinib tablets 120 mg administered twice daily with a meal starting on Day 2
Other Name: ARQ 197

Detailed Description:

The study is designed to estimate the maximum change in QTcF (change from baseline) between placebo and multiple-dose tivantinib. A tivantinib oral dose of 360 mg BID has been selected for this study because this is the highest dose currently being evaluated in clinical studies.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must have a histologically or cytologically confirmed advanced solid tumor at Screening
  • Male or female greater than or equal to 18 years of age
  • Women of childbearing potential must have a negative pregnancy test performed prior to the start of study drug
  • Subjects (male and female) of childbearing potential must agree to use double barrier contraceptive measures or avoid intercourse during the study and for 90 days after the last dose of study drug. In addition, all female subjects of childbearing potential must have a negative pregnancy test result before initiating study treatment
  • An Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 2
  • Adequate bone marrow and liver function, defined as:
  • Platelet count greater than or equal to 100 × 109/L
  • Hemoglobin greater than or equal to 9.0 g/dL
  • Absolute neutrophil count greater than or equal to 1.5 × 109/L
  • Total bilirubin less than or equal to 1.5 × upper limit of normal (ULN)
  • Alanine aminotransferase and aspartate aminotransferase less than or equal to 3 × ULN (less than or equal to 5 × ULN for subjects with liver metastases)
  • Serum creatinine less than or equal to 1.5 × ULN
  • Electrolytes within normal limits, particularly potassium, magnesium, & calcium. Supplementation is permitted as needed
  • Subjects should be able to provide written informed consent, comply with protocol visits and procedures, be able to take oral medication, and not have any active infection or chronic co-morbidity that would interfere with therapy
  • Subjects must be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects) and must sign and date an IRB-approved ICF (including HIPAA authorization, if applicable) before performance of any study-specific procedures or tests

Exclusion Criteria:

  • History of cardiac disease:
  • Active coronary artery disease, defined as myocardial infarction, unstable angina, coronary bypass graft, or stenting within 6 months prior to study entry
  • Evidence of uncontrolled bradycardia or other cardiac arrhythmia defined as greater than or equal to Grade 2 according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4, or uncontrolled hypertension
  • Any of the following ECG findings: PR interval greater than 240 msec or less than or equal to 110 msec or bradycardia defined as sinus rate <50 beats per minute
  • Mean QTcF interval greater than 450 msec on triplicate centrally read Screening ECGs
  • Cardiac conduction abnormalities denoted by any of the following: evidence of second-degree (type II) or third-degree atrioventricular block, evidence of ventricular pre-excitation, ECG evidence of complete left bundle branch block, intraventricular conduction delay with QRS duration greater than 120 msec, atrial fibrillation, or presence of cardiac pacemaker
  • Personal or family history of long-QT syndrome
  • Active, clinically serious infections defined as greater than or equal to Grade 2 according to NCI CTCAE, version 4
  • Known metastatic brain or meningeal tumors, unless that subject is greater than 3 months from definitive therapy and clinically stable (supportive therapy with steroids or anticonvulsant medications is allowed) with respect to the tumor at the time of first dose of study drug
  • Pregnant or breastfeeding
  • Any major surgical procedure within 3 weeks prior to the first dose of study drug
  • Significant gastrointestinal disorders, in the opinion of the Principal Investigator (eg, Crohn's disease, ulcerative colitis, extensive gastric resection, comorbid disease which causes malabsorption of the drug)
  • Received tivantinib as prior therapy
  • Received anticancer therapy, including antibody, retinoid, or hormonal treatment (except megestrol acetate as supportive care), and radiation, within 3 weeks before dosing. Prior and concurrent use of hormone replacement therapy, the use of gonadotropin-releasing hormone modulators for prostate cancer, and the use of somatostatin and analogs for neuroendocrine tumors are permitted
  • Any other investigational drug within 3 weeks prior to dosing
  • Substance abuse or medical, psychological, or social conditions that may, in the opinion of the Investigator, interfere with the subject's participation in the clinical study or evaluation of the clinical study results
  • Any condition that is unstable or that could jeopardize the safety of the subject and the subject's protocol compliance, including known infection with human immunodeficiency virus, hepatitis B virus, or hepatitis C virus
  • Inability to swallow oral medications that could interfere with the absorption of tivantinib
  • Administration or possibility of initiating or continuing any treatment with any known CYP 3A4 and CYP2C19 enzyme and P-glycoprotein altering drugs (inducer or inhibitor) or non-drug agents or gastric pH modifiers within the 14 days prior to dosing and/or during the PK evaluation (14 to 15 days) after initiation of the study treatment
  • Subjects with a clinical diagnosis of hepatic impairment and/or hepatocellular carcinoma and/or chronic liver cirrhosis with confirmation either by previous biopsy or with findings on ultrasound, computed tomography (CT) or MRI consistent with chronic liver cirrhosis
  • Subjects who are on treatment receiving drugs that may affect QTc (eg, quinidine or moxifloxacin)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01699061

Locations
United States, Texas
START - South Texas Accelerated Research Therapeutics, LLC
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Daiichi Sankyo Inc.
Medpace, Inc.
Investigators
Study Director: Hamim Zahir, BPharm, PhD Daiichi-Sankyo Pharma Development
  More Information

No publications provided

Responsible Party: Daiichi Sankyo Inc.
ClinicalTrials.gov Identifier: NCT01699061     History of Changes
Other Study ID Numbers: ARQ197-A-U-159
Study First Received: October 1, 2012
Last Updated: September 30, 2013
Health Authority: United States: Food and Drug Administration

ClinicalTrials.gov processed this record on November 20, 2014